Multiple roles of the coagulation protease cascade during virus infection

Blood

Volumn 123, Issue 17, 2014, Pages 2605-2613

  Antoniak, Silvio ^a   MacKman, Nigel ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BLOOD CLOTTING FACTOR 10; HEPARIN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 4; THROMBOPLASTIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ADENOVIRUS; ADENOVIRUS INFECTION; ARTICLE; BLEEDING; BLOOD CLOTTING; COXSACKIE VIRUS B; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; DENGUE VIRUS; DISSEMINATED INTRAVASCULAR CLOTTING; EBOLA HEMORRHAGIC FEVER; ENDOTHELIUM CELL; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION REGULATION; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; INNATE IMMUNITY; KNOCKOUT MOUSE; LIFE CYCLE; MACROPHAGE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIREMIA; VIRUS CAPSID; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS MYOCARDITIS;

ANIMALS; BLOOD COAGULATION; DENGUE VIRUS; FACTOR VIIA; HEPATOCYTES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; MACROPHAGES; MICE; MODELS, BIOLOGICAL; MYOCARDITIS; PEPTIDE HYDROLASES; RECEPTOR, PAR-1; RECEPTOR, PAR-2; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; VIRUS DISEASES;

EID: 84899629353     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-526277     Document Type: Article

References (100)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6): 805-820.
2. Beutler BA. TLRs and innate immunity. Blood. 2009;113(7): 1399-1407.
3. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164): 819-826.
4. Li C, Li J, Li Y, et al. Crosstalk between platelets and the immune system: old systems with new discoveries. Adv Hematol. 2012;2012: 384685.
5. Gorbea C, Makar KA, Pauschinger M, et al. A role for Toll-like receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. J Biol Chem. 2010; 285(30): 23208-23223.
6. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006; 441(7089): 101-105.
7. Fensterl V, Sen GC. Interferons and viral infections. Biofactors. 2009;35(1): 14-20.
8. Seya T, Matsumoto M, Ebihara T, Oshiumi H. Functional evolution of the TICAM-1 pathway for extrinsic RNA sensing. Immunol Rev. 2009; 227(1): 44-53.
9. Yuan J, Liu Z, Lim T, et al. CXCL10 inhibits viral replication through recruitment of natural killer cells in coxsackievirus B3-induced myocarditis. Circ Res. 2009;104(5): 628-638.
10. Key NS, Vercellotti GM, Winkelmann JC, et al. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci USA. 1990;87(18): 7095-7099.
11. Geisbert TW, Young HA, Jahrling PB, Davis KJ, Kagan E, Hensley LE. Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: overexpression of tissue factor in primate monocytes/macrophages is a key event. J Infect Dis. 2003;188(11): 1618-1629.
12. Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood. 2010;115(2): 161-167.
13. Huerta-Zepeda A, Cabello-Gutiérrez C, Cime-Castillo J, et al. Crosstalk between coagulation and inflammation during Dengue virus infection. Thromb Haemost. 2008;99(5): 936-943.
14. Antoniak S, Boltzen U, Riad A, et al. Viral myocarditis and coagulopathy: increased tissue factor expression and plasma thrombogenicity. J Mol Cell Cardiol. 2008;45(1): 118-126.
15. Antoniak S, Owens AP III, Baunacke M, et al. PAR-1 contributes to the innate immune response during viral infection. J Clin Invest. 2013;123(3): 1310-1322.
16. Goeijenbier M, van Wissen M, van de Weg C, et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol. 2012; 84(10): 1680-1696.
17. Shibamiya A, Hersemeyer K, Schmidt Wöll T, et al. A key role for Toll-like receptor-3 in disrupting the hemostasis balance on endothelial cells. Blood. 2009;113(3): 714-722.
18. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet. 2003; 362(9400): 1953-1958.
19. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000; 407(6801): 258-264.
20. Antoniak S, Pawlinski R, Mackman N. Proteaseactivated receptors and myocardial infarction. IUBMB Life. 2011;63(6): 383-389.
21. Shpacovitch V, Feld M, Hollenberg MD, Luger TA, Steinhoff M. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol. 2008; 83(6): 1309-1322.
22. Lan RS, Stewart GA, Goldie RG, Henry PJ. Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286(2):L388-L398.
23. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67(1): 2-11.
24. Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br J Pharmacol. 2010;160(2): 191-203.
25. Nhu QM, Shirey KA, Pennini ME, Stiltz J, Vogel SN. Proteinase-activated receptor 2 activation promotes an anti-inflammatory and alternatively activated phenotype in LPS-stimulated murine macrophages. Innate Immun. 2012;18(2): 193-203.
26. Sutherland MR, Ruf W, Pryzdial EL. Tissue factor and glycoprotein C on herpes simplex virus type 1 are protease-activated receptor 2 cofactors that enhance infection. Blood. 2012; 119(15): 3638-3645.
27. Sutherland MR, Friedman HM, Pryzdial EL. Herpes simplex virus type 1-encoded glycoprotein C enhances coagulation factor VIIa activity on the virus. Thromb Haemost. 2004; 92(5): 947-955.
28. Etingin OR, Silverstein RL, Friedman HM, Hajjar DP. Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. Cell. 1990;61(4): 657-662.
29. Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100(5): 859-865.
30. Sutherland MR, Friedman HM, Pryzdial EL. Thrombin enhances herpes simplex virus infection of cells involving protease-activated receptor 1. J Thromb Haemost. 2007;5(5): 1055-1061.
31. Sutherland MR, Simon AY, Shanina I, Horwitz MS, Ruf W, Pryzdial EL. Tissue factor on the herpes simplex virus type 1 surface enhances infection in vivo. In: 55th ASH Annual Meeting and Exhibition; December 7-10, 2013. New Orleans, LA. Abstract 2332.
32. Parker AL, Waddington SN, Nicol CG, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108(8): 2554-2561.
33. Waddington SN, McVey JH, Bhella D, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3): 397-409.
34. Coughlan L, Alba R, Parker AL, et al. Tropismmodification strategies for targeted gene delivery using adenoviral vectors. Viruses. 2010;2(10): 2290-2355.
35. Xu Z, Qiu Q, Tian J, et al. Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med. 2013; 19(4): 452-457.
36. Doronin K, Flatt JW, Di Paolo NC, et al. Coagulation factor X activates innate immunity to human species C adenovirus. Science. 2012; 338(6108): 795-798.
37. Schuettrumpf J, Zou J, Zhang Y, et al. The inhibitory effects of anticoagulation on in vivo gene transfer by adeno-associated viral or adenoviral vectors. Mol Ther. 2006;13(1): 88-97.
38. Moretti S, Bellocchio S, Bonifazi P, et al. The contribution of PARs to inflammation and immunity to fungi. Mucosal Immunol. 2008;1(2): 156-168.
39. Antoniak S, Mackman N. Coagulation, protease-activated receptors, and viral myocarditis. J Cardiovasc Transl Res. 2014;7(2): 203-211.
40. Nhu QM, Shirey K, Teijaro JR, et al. Novel signaling interactions between proteinaseactivated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol. 2010;3(1): 29-39.
41. Rallabhandi P, Nhu QM, Toshchakov VY, et al. Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem. 2008; 283(36): 24314-24325.
42. Weithauser A, Bobbert P, Antoniak S, et al. Protease-activated receptor-2 regulates the innate immune response to viral infection in a coxsackievirus B3-induced myocarditis. J Am Coll Cardiol. 2013;62(19): 1737-1745.
43. Gleeson EM, O'Donnell JS, Hams E, et al. Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from LPS-stimulated myeloid cells. Haematologica. 2014;99(1): 185-193.
44. Pawlinski R, Pedersen B, Schabbauer G, et al. Role of tissue factor and protease-activated receptors in a mouse model of endotoxemia. Blood. 2004;103(4): 1342-1347.
45. Khoufache K, LeBouder F, Morello E, et al. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-gamma-dependent pathway. J Immunol. 2009;182(12): 7795-7802.
46. Antoniak S, Milner J, Beck MA, Mackman N. Protease-activated receptor 1 contributes to early immune responses in the lung after influenza A infection. In: XXIV Congress of the International Society on Thrombosis and Haemostasis; June 25-July 4, 2013. Amsterdam, NL. Abstract 849.
47. Blauwet LA, Cooper LT. Myocarditis. Prog Cardiovasc Dis. 2010;52(4): 274-288.
48. Riad A, Westermann D, Zietsch C, et al. TRIF is a critical survival factor in viral cardiomyopathy. J Immunol. 2011;186(4): 2561-2570.
49. Abston ED, Coronado MJ, Bucek A, et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 versus TRIF in progression to chronic disease. Clin Dev Immunol. 2012;2012: 129486.
50. Richer MJ, Lavallée DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is required for survival following coxsackievirus B4 infection. PLoS ONE. 2009;4(1):e4127.
51. Wessely R, Klingel K, Knowlton KU, Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: implications for mortality and early viral replication. Circulation. 2001;103(5): 756-761.
52. Stewart MJ, Smoak K, Blum MA, Sherry B. Basal and reovirus-induced beta interferon (IFN-beta) and IFN-beta-stimulated gene expression are cell type specific in the cardiac protective response. J Virol. 2005;79(5): 2979-2987.
53. Molino M, Barnathan ES, Numerof R, et al. Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem. 1997;272(7): 4043-4049.
54. Fairweather D, Frisancho-Kiss S, Gatewood S, et al. Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity. 2004;37(2): 131-145.
55. Higuchi H, Hara M, Yamamoto K, et al. Mast cells play a critical role in the pathogenesis of viral myocarditis. Circulation. 2008;118(4): 363-372.
56. Xing Y, Chen J, Tu J, et al. The papain-like protease of porcine epidemic diarrhea virus negatively regulates type I interferon pathway by acting as a viral deubiquitinase. J Gen Virol. 2013;94(Pt 7): 1554-1567.
57. Naldini A, Carney DH. Thrombin modulation of natural killer activity in human peripheral lymphocytes. Cell Immunol. 1996; 172(1): 35-42.
58. Jaffr é F, Friedman AE, Hu Z, Mackman N, Blaxall BC. b-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation. 2012;125(24): 2993-3003.
59. Frizelle S, Schwarz J, Huber SA, Leslie K. Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice. Am J Pathol. 1992; 141(1): 203-209.
60. Malz R, Weithaeuser A, Tschöpe C, Schultheiss HP, Rauch U. Inhibition of coagulation factor Xa improves myocardial function during CVB3- induced myocarditis [published online ahead of print February 17, 2014]. Cardiovasc Ther.
61. Schnitt SJ, Stillman IE, Owings DV, Kishimoto C, Dvorak HF, Abelmann WH. Myocardial fibrin deposition in experimental viral myocarditis that progresses to dilated cardiomyopathy. Circ Res. 1993;72(4): 914-920.
62. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol. 2005; 166(5): 1353-1365.
63. Vivès RR, Lortat-Jacob H, Fender P. Heparan sulphate proteoglycans and viral vectors : ally or foe? Curr Gene Ther. 2006;6(1): 35-44.
64. Zautner AE, Körner U, Henke A, Badorff C, Schmidtke M. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol. 2003;77(18): 10071-10077.
65. Sun X, Tse LV, Ferguson AD, Whittaker GR. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J Virol. 2010;84(17): 8683-8690.
66. Le Goffic R, Pothlichet J, Vitour D, et al. Cutting Edge: Influenza A virus activates TLR3- dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol. 2007;178(6): 3368-3372.
67. Le Goffic R, Balloy V, Lagranderie M, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2006;2(6):e53.
68. Feld M, Shpacovitch VM, Ehrhardt C, et al. Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: role in influenza A infection. J Immunol. 2008;180(10): 6903-6910.
69. Lan RS, Stewart GA, Henry PJ. Modulation of airway smooth muscle tone by protease activated receptor-1,-2,-3 and -4 in trachea isolated from influenza A virus-infected mice. Br J Pharmacol. 2000;129(1): 63-70.
70. Pan HY, Yano M, Kido H. Effects of inhibitors of Toll-like receptors, protease-activated receptor-2 signalings and trypsin on influenza A virus replication and upregulation of cellular factors in cardiomyocytes. J Med Invest. 2011;58(1-2): 19-28.
71. Brandes M, Klauschen F, Kuchen S, Germain RN. A systems analysis identifies a feedforward inflammatory circuit leading to lethal influenza infection. Cell. 2013;154(1): 197-212.
72. Shpacovitch V, Feld M, Bunnett NW, Steinhoff M. Protease-activated receptors: novel PARtners in innate immunity. Trends Immunol. 2007; 28(12): 541-550.
73. Chignard M, Pidard D. Neutrophil and pathogen proteinases versus proteinase-activated receptor-2 lung epithelial cells: more terminators than activators. Am J Respir Cell Mol Biol. 2006; 34(4): 394-398.
74. Betts RJ, Mann TS, Henry PJ. Inhibitory influence of the hexapeptidic sequence SLIGRL on influenza A virus infection in mice. J Pharmacol Exp Ther. 2012;343(3): 725-735.
75. Seitz C, Isken B, Heynisch B, Rettkowski M, Frensing T, Reichl U. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol. 2012;93(2): 601-611.
76. Gotoh B, Ogasawara T, Toyoda T, Inocencio NM, Hamaguchi M, Nagai Y. An endoprotease homologous to the blood clotting factor X as a determinant of viral tropism in chick embryo. EMBO J. 1990;9(12): 4189-4195.
77. Khoufache K, Berri F, Nacken W, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013;123(1): 206-214.
78. Aerts L, Hamelin M-È, Rhéaume C, et al. Modulation of protease activated receptor 1 influences human metapneumovirus disease severity in a mouse model. PLoS ONE. 2013; 8(8):e72529.
79. Berri F, Lê VB, Jandrot-Perrus M, Lina B, Riteau B. Switch from protective to adverse inflammation during influenza: viral determinants and hemostasis are caught as culprits. Cell Mol Life Sci. 2014;71(5): 885-898.
80. Schouten M, Sluijs KF, Gerlitz B, et al. Activated protein C ameliorates coagulopathy but does not influence outcome in lethal H1N1 influenza: a controlled laboratory study. Crit Care. 2010; 14(2):R65.
81. Schouten M, van der Sluijs KF, Roelofs JJ, Levi M, Van't Veer C, van der Poll T. Factor V Leiden mutation does not affect coagulopathy or outcome in lethal H1N1 influenza. Eur Respir J. 2010;36(6): 1346-1354.
82. Keller TT, van der Sluijs KF, de Kruif MD, et al. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res. 2006;99(11): 1261-1269.
83. Schouten M, de Boer JD, van der Sluijs KF, et al. Impact of endogenous protein C on pulmonary coagulation and injury during lethal H1N1 influenza in mice. Am J Respir Cell Mol Biol. 2011;45(4): 789-794.
84. Gilbert CR, Vipul K, Baram M. Novel H1N1 influenza A viral infection complicated by alveolar hemorrhage. Respir Care. 2010;55(5): 623-625.
85. Starko KM. Salicylates and pandemic influenza mortality, 1918-1919 pharmacology, pathology, and historic evidence. Clin Infect Dis. 2009; 49(9): 1405-1410.
86. Eyers S, Weatherall M, Shirtcliffe P, Perrin K, Beasley R. The effect on mortality of antipyretics in the treatment of influenza infection: systematic review and meta-analysis. J R Soc Med. 2010; 103(10): 403-411.
87. Antoniak S, Tatsumi K, Milner J, Beck MA, Mackman N. Impaired hemostasis leads to alveolar hemorrhages and increased mortality in influenza A infection. In: 55th ASH Annual Meeting and Exhibition; December 7-10, 2013. New Orleans, LA. Abstract 1095.
88. Berri F, Rimmelzwaan GF, Hanss M, et al. Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. PLoS Pathog. 2013;9(3):e1003229.
89. Gubler DJ. The economic burden of dengue. Am J Trop Med Hyg. 2012;86(5): 743-744.
90. Suharti C, van Gorp EC, Setiati TE, et al. The role of cytokines in activation of coagulation and fibrinolysis in dengue shock syndrome. Thromb Haemost. 2002;87(1): 42-46.
91. Lin YS, Yeh TM, Lin CF, et al. Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. Exp Biol Med (Maywood). 2011;236(5): 515-523.
92. Cabello-Gutiérrez C, Manjarrez-Zavala ME, Huerta-Zepeda A, et al. Modification of the cytoprotective protein C pathway during Dengue virus infection of human endothelial vascular cells. Thromb Haemost. 2009;101(5): 916-928.
93. Baker JV, Brummel-Ziedins K, Neuhaus J, et al; INSIGHT SMART Study Team. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc. 2013;2(4): e000264.
94. Kuller LH, Tracy R, Belloso W, et al; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
95. Acharjee S, Zhu Y, Maingat F, et al. Proteinaseactivated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain. 2011;134(Pt 11): 3209-3221.
96. Boven LA, Vergnolle N, Henry SD, et al. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol. 2003;170(5): 2638-2646.
97. Giacaman RA, Nobbs AH, Ross KF, Herzberg MC. Porphyromonas gingivalis selectively upregulates the HIV-1 coreceptor CCR5 in oral keratinocytes. J Immunol. 2007;179(4): 2542-2550.
98. Fabrizi C, Pompili E, Panetta B, Nori SL, Fumagalli L. Protease-activated receptor-1 regulates cytokine production and induces the suppressor of cytokine signaling-3 in microglia. Int J Mol Med. 2009;24(3): 367-371.
99. Zhou Y, Wang X, Liu M, et al. A critical function of toll-like receptor-3 in the induction of antihuman immunodeficiency virus activities in macrophages. Immunology. 2010;131(1): 40-49.
100. Hurley A, Smith M, Karpova T, et al. Enhanced effector function of CD8(1) T cells from healthy controls and HIV-infected patients occurs through thrombin activation of proteaseactivated receptor 1. J Infect Dis. 2013;207(4): 638-650.